BACKGROUND: AIDS-defining events (ADEs) decreased in the era of highly active antiretroviral therapy but still lead to hospitalizations and deaths. Understanding factors related to ADEs is important to mitigate events. METHODS: We examined the relationship between demographics, behaviors, comorbidities, laboratory, clinical measurements, and ADEs diagnosed among subjects randomized to antiretroviral treatments (ART)/strategies and followed prospectively. Logistic regression models using generalized estimating equations generated odds ratios (ORs) focusing on the relationship between current CD4 T-cell count (CD4)/HIV-1 RNA viral load (VL) and ADEs in the subsequent 16-week study period. RESULTS: Among the 2948 subjects in the analysis, overall incidence of ADEs was 1.53 per 100 person-years. Multivariate regression models adjusted for demographics, body mass index, and ADE history. A 6-level time-varying variable examined VL (>100,000 copies/mL, < or =100,000) at CD4 levels (0-50, 51-200, >200 cells/microL); reference level was CD4 >200/VL < or =100,000. Among ART naives, odds of having an ADE in the subsequent 16-week interval were greater among subjects with lower CD4 counts; this relationship was modified by VL level (CD4 < or =50/VL >100,000: OR 37.2; CD4 < or =50/VL < or =100,000: OR 30.5; CD4 51-200/VL >100,000: OR 13.0; CD4 51-200/VL < or =100,000: OR 4.5; all P values <0.001). Similar results were seen among ART-experienced subjects. CONCLUSIONS: Recent CD4 and VL values are closely associated with development of ADEs even after examining a multitude of potential factors.
RCT Entities:
BACKGROUND:AIDS-defining events (ADEs) decreased in the era of highly active antiretroviral therapy but still lead to hospitalizations and deaths. Understanding factors related to ADEs is important to mitigate events. METHODS: We examined the relationship between demographics, behaviors, comorbidities, laboratory, clinical measurements, and ADEs diagnosed among subjects randomized to antiretroviral treatments (ART)/strategies and followed prospectively. Logistic regression models using generalized estimating equations generated odds ratios (ORs) focusing on the relationship between current CD4 T-cell count (CD4)/HIV-1 RNA viral load (VL) and ADEs in the subsequent 16-week study period. RESULTS: Among the 2948 subjects in the analysis, overall incidence of ADEs was 1.53 per 100 person-years. Multivariate regression models adjusted for demographics, body mass index, and ADE history. A 6-level time-varying variable examined VL (>100,000 copies/mL, < or =100,000) at CD4 levels (0-50, 51-200, >200 cells/microL); reference level was CD4 >200/VL < or =100,000. Among ART naives, odds of having an ADE in the subsequent 16-week interval were greater among subjects with lower CD4 counts; this relationship was modified by VL level (CD4 < or =50/VL >100,000: OR 37.2; CD4 < or =50/VL < or =100,000: OR 30.5; CD4 51-200/VL >100,000: OR 13.0; CD4 51-200/VL < or =100,000: OR 4.5; all P values <0.001). Similar results were seen among ART-experienced subjects. CONCLUSIONS: Recent CD4 and VL values are closely associated with development of ADEs even after examining a multitude of potential factors.
Authors: John T Brooks; Jonathan E Kaplan; King K Holmes; Constance Benson; Alice Pau; Henry Masur Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Marlene Smurzynski; Ann C Collier; Susan L Koletar; Ronald J Bosch; Kunling Wu; Barbara Bastow; Constance A Benson Journal: HIV Clin Trials Date: 2008 Jul-Aug
Authors: Janis V Giorgi; Robert H Lyles; Jose L Matud; Traci E Yamashita; John W Mellors; Lance E Hultin; Beth D Jamieson; Joseph B Margolick; Charles R Rinaldo; John P Phair; Roger Detels Journal: J Acquir Immune Defic Syndr Date: 2002-04-01 Impact factor: 3.731
Authors: Rodger D MacArthur; George Perez; Sharon Walmsley; John D Baxter; Christopher M Mullin; James D Neaton Journal: HIV Clin Trials Date: 2005 May-Jun
Authors: B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti Journal: JAMA Date: 1999-12-15 Impact factor: 56.272
Authors: Kate Buchacz; Rose K Baker; Anne C Moorman; James T Richardson; Kathleen C Wood; Scott D Holmberg; John T Brooks Journal: AIDS Date: 2008-07-11 Impact factor: 4.177
Authors: Jason V Baker; Grace Peng; Joshua Rapkin; Donald I Abrams; Michael J Silverberg; Rodger D MacArthur; Winston P Cavert; W Keith Henry; James D Neaton Journal: AIDS Date: 2008-04-23 Impact factor: 4.177
Authors: Susan L Koletar; Paige L Williams; Julia Wu; J Allen McCutchan; Susan E Cohn; Robert L Murphy; Howard M Lederman; Judith S Currier Journal: Clin Infect Dis Date: 2004-10-22 Impact factor: 9.079
Authors: Supriya Krishnan; Jeffrey T Schouten; Denise L Jacobson; Constance A Benson; Ann C Collier; Susan L Koletar; Jorge Santana; Fred R Sattler; Ronald Mitsuyasu Journal: Oncology Date: 2011-05-23 Impact factor: 2.935
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas Journal: Clin Infect Dis Date: 2013-02-05 Impact factor: 9.079
Authors: Christopher J Hoffmann; Michael Schomaker; Matthew P Fox; Portia Mutevedzi; Janet Giddy; Hans Prozesky; Robin Wood; Daniela B Garone; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Marlene Smurzynski; Kunling Wu; Jeffrey T Schouten; Judith J Lok; Ronald J Bosch; Babafemi Taiwo; Victoria Anne Johnson; Ann C Collier Journal: AIDS Date: 2013-07-31 Impact factor: 4.177
Authors: Jennifer Gillis; Mona Loutfy; Ahmed M Bayoumi; Tony Antoniou; Ann N Burchell; Sharon Walmsley; Curtis Cooper; Marina B Klein; Nima Machouf; Julio S G Montaner; Sean B Rourke; Christos Tsoukas; Robert Hogg; Janet Raboud Journal: J Acquir Immune Defic Syndr Date: 2016-12-15 Impact factor: 3.731